PT - JOURNAL ARTICLE AU - Gray, Kathryn J. AU - Bordt, Evan A. AU - Atyeo, Caroline AU - Deriso, Elizabeth AU - Akinwunmi, Babatunde AU - Young, Nicola AU - Baez, Aranxta Medina AU - Shook, Lydia L. AU - Cvrk, Dana AU - James, Kaitlyn AU - De Guzman, Rose M. AU - Brigida, Sara AU - Diouf, Khady AU - Goldfarb, Ilona AU - Bebell, Lisa M. AU - Yonker, Lael M. AU - Fasano, Alessio AU - Rabi, Sayed A. AU - Elovitz, Michal A. AU - Alter, Galit AU - Edlow, Andrea G. TI - COVID-19 vaccine response in pregnant and lactating women: a cohort study AID - 10.1101/2021.03.07.21253094 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.07.21253094 4099 - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253094.short 4100 - http://medrxiv.org/content/early/2021/03/08/2021.03.07.21253094.full AB - Background Pregnant and lactating women were excluded from initial COVID-19 vaccine trials; thus, data to guide vaccine decision-making are lacking. We sought to evaluate the immunogenicity and reactogenicity of COVID-19 mRNA vaccination in pregnant and lactating women.Methods 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 non-pregnant) were enrolled in a prospective cohort study at two academic medical centers. Titers of SARS-CoV-2 Spike and RBD IgG, IgA and IgM were quantified in participant sera (N=131), umbilical cord sera (N=10), and breastmilk (N=31) at baseline, 2nd vaccine dose, 2-6 weeks post 2nd vaccine, and delivery by Luminex, and confirmed by ELISA. Titers were compared to pregnant women 4-12 weeks from native infection (N=37). Post-vaccination symptoms were assessed. Kruskal-Wallis tests and a mixed effects model, with correction for multiple comparisons, were used to assess differences between groups.Results Vaccine-induced immune responses were equivalent in pregnant and lactating vs non-pregnant women. All titers were higher than those induced by SARS-CoV-2 infection during pregnancy. Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. SARS-CoV-2 specific IgG, but not IgA, increased in maternal blood and breastmilk with vaccine boost. No differences were noted in reactogenicity across the groups.Conclusions COVID-19 mRNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in non-pregnant women. Vaccine-induced immune responses were significantly greater than the response to natural infection. Immune transfer to neonates occurred via placental and breastmilk.Competing Interest StatementDr. Gray has consulted for Illumina, BillionToOne, and Aetion outside the submitted work. Dr. Fasano reported serving as a cofounder of and owning stock in Alba Therapeutics and serving on scientific advisory boards for NextCure and Viome outside the submitted work. Dr. Alter reported serving as a founder of Systems Seromyx. All other authors report no conflicts of interest.Funding StatementThis work was supported by the National Institutes of Health, including NICHD (grants R01HD100022 and 3R01HD100022-02S20) (to AGE), NHLBI (grants K08HL1469630-02 and 3K08HL146963-02S1) (to KJG). Additional support was provided by NIAID (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, 1U01CA260476 – 01), the Gates Foundation, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the Musk Foundation, the Ragon Institute of MGH and MIT and the Massachusetts General Hospital and Brigham and Women’s Hospital Departments of Obstetrics and Gynecology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all patients. All samples collected were approved by the Mass General Brigham Institutional Review Board (protocols 2020P003538 and 2020P000804).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request.